Complete coverage on


Latest Stories

Help me understand my cholesterol drugsupdated: Thu Jan 28 2010 12:38:00

Hi, I'm 55 and have high cholesterol. I've been on Lipitor, Zocor and Provacol. They have tested me several times in recent years, and the statin drugs are messing up my liver enzymes. My new doctor is planning on putting me on Zetia. Now I'm hearing there are concerns about Zetia. Do you know what they are concerned about?

Half avoid rotavirus vaccineupdated: Mon Apr 21 2008 13:33:00

CNN's Dr. Sanjay Gupta reports on the CDC's recommendation that parents vaccinate for rotavirus.

CNNMoney: Merck profit strong, sales weakupdated: Mon Apr 21 2008 13:33:00

Merck said Monday its first-quarter earnings jumped due to income from a partnership, but the drugmaker's sales showed just a slight gain.

CNNMoney: Schering stock jumps on job cutsupdated: Thu Apr 03 2008 12:44:00

Schering-Plough's stock jumped Thursday, after the drugmaker's chief executive announced he would cut 10% of its staff.

Can surgery cure diabetes?updated: Fri Jan 25 2008 17:08:00

CNN's Dr. Sanjay Gupta examines recent studies that show Type 2 diabetes could vanish after bariatric surgery.

CNNMoney: FDA scrutinizes Vytorinupdated: Fri Jan 25 2008 17:08:00

Government regulators said Friday they are analyzing recent study results regarding cholesterol drug Vytorin, but that it's too early to tell whether it will take any regulatory action.

Stop snoring!updated: Tue Oct 02 2007 14:12:00

England's government is set to pay for pressurized air masks that combat sleep apnea. CNN's Alphonso Van Marsh reports.

CNNMoney: Schering pushing hard to diversifyupdated: Tue Oct 02 2007 14:12:00

Drugmaker Schering-Plough is a favorite of analysts and investors these days. It's no wonder: The company's flagship product, the cholesterol-fighting Vytorin, is breaking sales records and faces relatively little risk from cheaper generic versions from rivals.

CNNMoney: Schering-Plough profits riseupdated: Sun Jul 22 2007 21:50:00

Schering-Plough Corp. said Monday that second-quarter earnings rose sharply, fueled by growing demand for its Zetia and Vytorin cholesterol drugs and treatments for arthritis and allergies.

CNNMoney: Tough day for heart drugsupdated: Mon Mar 19 2007 11:05:00

An experimental drug from AtheroGenics and its partner AstraZeneca failed a late-stage clinical trial and is not considered an effective treatment in reducing heart disease, the companies said.

Fortune: Serwer: 2 winners and a very soft shoeupdated: Wed Aug 30 2006 08:19:00

All this reading of the tea leaves of Fed meeting minutes makes my brain hurt! I mean talk about white noise. Here's a question: Will the action pick up after Labor Day?

CNNMoney: Vytorin is better than Crestor, says study from Merck, Schering-Ploughupdated: Mon Jun 19 2006 06:00:00

Merck and Schering-Plough announced a study on Sunday showing that their combination drug Vytorin is better at lowering cholesterol than competing drug Crestor from AstraZeneca.

CNNMoney: Schering-Plough's big bet against Pfizerupdated: Wed Mar 15 2006 10:12:00

Schering-Plough, once the troubled child of the drug industry, is making a comeback with a hot new drug.

CNNMoney: Merck claims Vytorin beats Zocorupdated: Mon Mar 13 2006 08:13:00

A new study shows that Vytorin, a cholesterol drug from Merck and Schering-Plough that combines Zocor and Zetia, significantly reduces cholesterol when compared to Zocor alone, the company said.

CNNMoney: Vytorin outsells rival cholesterol drugsupdated: Tue Jul 26 2005 13:19:00

Vytorin, a relatively new cholesterol-blocking drug from Merck and Schering-Plough, has outpaced sales of a blockbuster rival, according to a report Monday from Friedman, Billings, Ramsey & Co.

CNNMoney: Vytorin sales rise during debut year.updated: Mon Jun 20 2005 13:57:00

Sales for Vytorin, a cholesterol-treating combination produced by Merck and Schering-Plough, have grown since its market debut last summer, but the drug's real test lies ahead, analysts say.

Money Magazine: Funds: A knack for discoveryupdated: Thu Nov 06 2003 17:29:00

In an industry characterized by change, Samuel Isaly has been a rare constant.

Money Magazine: A Knack For Discovery Veteran fund manager Samuel Isaly of Eaton Vance Worldwide Health Sciences has a nose updated: Sat Nov 01 2003 00:01:00

In an industry characterized by change, Samuel Isaly has been a rare constant. Since becoming a drug analyst at age 23, after graduating from the London School of Economics, the manager of the $2 ...

Money Magazine: 10 drug stocks to watchupdated: Mon Mar 24 2003 15:43:00

In the future, successful drug companies will have to come up with innovative cures for complex, hard-to-treat conditions like cancer -- without letting their research-and-development spending get out of hand.

Fortune: Pfizer Feeds Its Drug Habitupdated: Mon Aug 12 2002 00:01:00

While Wall Street wants to break conglomerates into smithereens, the pharmaceuticals business is heading in the opposite direction. If approved, Pfizer's $60 billion purchase of Pharmacia will crea...

We recommend